New combo aims to revive immune attack on tough lung cancers

NCT ID NCT07158489

Not yet recruiting Disease control Sponsor: Swiss Cancer Institute Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 37 times

Summary

This study tests a new two-drug combination for people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy and chemotherapy. The drugs—gemcitabine (a chemotherapy) and ivonescimab (a targeted therapy)—are given together to try to shrink tumors. About 47 adults will take part, and the main goal is to see how many patients have their tumors shrink significantly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hôpital Fribourgeois - Hôpital Cantonal

Fribourg, Switzerland
Hôpitaux Universitaires de Genève

Geneva, 1211, Switzerland
IOSI Ospedale Regionale di Bellinzona e Valli

Bellinzona, 6500, Switzerland
Kantonsspital Baden

Baden, 5404, Switzerland
Kantonsspital Graubuenden

Chur, CH-7000, Switzerland
Kantonsspital Winterthur

Winterthur, 8401, Switzerland
Universitätsspital Basel

Basel, 4031, Switzerland

Conditions

Explore the condition pages connected to this study.

NSCLC NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)